öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º¹ù´´ÐÂ
ÐÔ±ð£ºÄÐ
ÈËÆøÖ¸Êý£º627

ËùÊôԺУ£ºÊ¯ºÓ×Ó´óѧ
ËùÊôԺϵ£ºÒ©Ñ§Ôº
Ö°³Æ£ºÎ´ÆÀ¶¨
µ¼Ê¦ÀàÐÍ£º
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£ºÒ©Ñ§
Ñо¿ÁìÓò£º »¯Ñ§¡¢
Ñо¿ÁìÓò£º »¯Ñ§¡¢ [ÊÕÆð]




ͨѶ·½Ê½ :
°ì¹«µç»°£º**
µç×ÓÓʼþ£ºcxguo@kintor.com.cn
ͨѶµØÖ·£ºËÕÖݹ¤ÒµÔ°ÇøÐǺþ½Ö218ºÅÉúÎïÄÉÃ×Ô°C4Â¥401ËÕÖÝ¿ªÍØÒ©Òµ


¸öÈ˼òÊö :
1990ÄêÔÚ±±¾©´óѧ»ñµÃ»¯Ñ§Ñ§Ê¿ºó¡¢½øÈëPurdue´óѧ¹¥¶ÁÓлú»¯Ñ§²©Ê¿Ñ§Î»¡£±ÏÒµºóµÄ15ÄêÔÚÃÀ¹ú¿ç¹úÒ©Òµ¹«Ë¾ÈÎÒ½Ò©»¯Ñ§ºÍ»¯Ñ§¹¤Òպϳɲ¿ÃÅÖ÷¹Ü£¬Ö±½Ó²ÎÓëÁìµ¼¶àÏîÐÂÒ©¿ª·¢£¬³ýÁËÏȵ¼ÎïµÄÈ·ÈϺÍÓÅ»¯£¬»¹¸ºÔðºòÑ¡»¯ºÏÎïµÄÉú²ú¹¤ÒÕµÄÓÅ»¯ºÍ·Å´ó£¬²¢Ê¹¶à¸öС·Ö×Ó»¯ºÏÎï½øÈëÁÙ´²Ç°ºÍÁÙ´²µÄ·¢Õ¹£¬¹ù²©Ê¿ÔÚ»¯ºÏÎïºÏ³É¹¤ÒÕºÍÒ©ÎïÉè¼ÆÑо¿ÁìÓò·¢±íÁËÎåÊ®¶àƪÐí¶àÂÛÎĺÍרÀû¡£2013Äê»ñµÃÁËÖÐ×鲿µÚ¾ÅÅú´´ÐÂÀࡰǧÈ˼ƻ®¡±ÌØƸר¼Ò³ÆºÅ¡£¹ù²©Ê¿ÔÚÃÀÁôѧÆڼ䣬ÏȺóÔÚŦԼÖÝÁ¢´óѧ»ñÓлú»¯Ñ§Ë¶Ê¿Ñ§Î»£¨1994Ä꣩¡¢Æնɴóѧ»ñµÃÓлú»¯Ñ§²©Ê¿Ñ§Î»£¨1998Ä꣩£¬ËûÔÚÑо¿Éú£¨Ë¶Ê¿ºÍ²©Ê¿£©ÆÚ¼äרÃÅ´ÓÊ¿¹°©ÌìÈ»²úÎïµÄÈ«ºÏ³É£¬È¡µÃ¶àÏîÏÔÖø³É¹û£¬ÌرðÊǹ¥¿ËÁ˶à¸öºÏ³ÉÄѹØ£¬³É¹¦µØÍê³ÉÁËÈý¸ö½á¹¹¸÷Òì¶øÓַdz£¸´ÔӵĿ¹°©ÌìÈ»²úÎThiarubrine A, Cephalostatin 1 ºÍ OSW-1£©µÄÈ«ºÏ³É£¨¾ùΪÊÀ½çÊ״Σ©£¬ÔÚ¾ßÓÐÓ°ÏìÁ¦µÄѧÊõÔÓÖ¾ÉÏ·¢±íÁË13ƪÎÄÕ£¨ÆäÖÐÆßƪÔÚÖøÃûµÄJ. Am. Chem. Soc. [Ó°ÏìÒò×Óimpact factor 9.0]£©ºÍÒ»ÏîרÀû£¨US **£¬×÷ΪΨһµÄѧÉúÓë½ÌÊÚÁªÃûÉêÇ룩£¬»ñµÃ¶àÏîÈÙÓþ£¬°üÀ¨ÃÀ¹ú¹ú¼Ò¿Æѧ»ù½ð»á½±Ñ§½ð£¨NSF fellowship, 1996-1998Ä꣩¡¢Æնɰ©Ö¢Ñо¿ÖÐÐÄDavid Ross ½±Ñ§½ð £¨1996-1997Ä꣩¼°Monsanto Ñо¿ÉúѧÊõ»áÒ齱ѧ½ð£¨1998Ä꣩¡£

¹ù²©Ê¿ÔÚÃÀ¹ú¿ç¹úÒ©Òµ¹«Ë¾»ÔÈð£¨Pfizer£©ÓÐ15ÄêµÄ¹¤×÷¾­Àú£¬ÔøÈÎÒ½Ò©»¯Ñ§²¿ÃÅÖ÷¹Ü£¬Ö±½Ó²ÎÓëÁìµ¼¶àÏîÐÂÒ©ÁÙ´²Ç°£¨2¸ö£©ºÍÁÙ´²£¨4¸ö£©µÄ·¢Õ¹¡£ËûÔÚ¹ú¼ÊÖøÃûµÄѧÊõ¿¯ÎïÉÏ£¨°üÀ¨Proceedings of the National Academy of Sciences of the United States of America [Ó°ÏìÒò×Óimpact factor 9.8]ºÍJ. Med. Chem. [Ó°ÏìÒò×Óimpact factor 5.2]£©·¢±í29ƪÂÛÎÄ£¨´ó¶àÊýΪµÚÒ»×÷Õß»òͨѶ×÷Õߣ©£¬Ò²ÊÇ11¸öרÀûµÄÖ÷Òª·¢Ã÷ÈË¡£Ëû·¢±íµÄ¹ØÓÚPAK4¼¤Ã¸ÒÖÖƼÁÐÂÒ©Ñз¢µÄÁ½ÆªÂÛÎÄ·Ö±ðÓÚ2010ÄêºÍ2012Äê±»ÊÀ½çÔÚÏßÉúÎïÒ½Ò©ÎÄÏ×¼ìË÷ȨÍþ»ú¹¹¡±Faculty of 1000¡±(F1000)ÆÀѡΪÉúÎïѧ¼°Ò½Ñ§Ñо¿ÈËÔ±±Ø¶ÁÂÛÎÄ£¬ÈëÑ¡ÂÛÎÄÊÇÓɶàλÊÀ½ç¶¥¼¶×¨¼ÒѧÕßÆÀ¼ÛÍƼöµÄ£¨±»ÆÀΪtop 2%µÄÂÛÎĵ±Ñ¡£©£¬ÂÛÎı»F1000ÊÕ¼²¢»ñµÃÍƼöÊǶԸÃÂÛÎĺÍÑо¿ÈËÔ±µÄºÜ¸ßÈÏ¿É¡£¹ù´´Ð²©Ê¿·¢±íÂÛÎĵÄH Index ÊÇ19¡¢ÒýÓôÎÊý: 1110 £¨https://scholar.google.com/citations?user=klurUg0AAAAJ&hl=en£©¡£

¹ù´´Ð²©Ê¿ÊÇÃÀ¹úÒÔÖÁÊÀ½çÖÆÒ©¹¤Òµ½ìÒ©ÎïºÏ³É¹¤ÒÕ»¯Ñ§ºÍ°©Ö¢ÐÂÒ©Ñо¿¿ª·¢£¨Cancer Drug Discovery£©·½ÃæµÄÖªÃûר¼Ò£¬µ£Èιý¶à¸ö¹ú¼ÊѧÊõÔÓÖ¾µÄÆÀÉó¨D¨DPNAS (IF£º10)¡¢J Med Chem (IF£º5)¡¢Curr Med Chem (IF£º5)¡¢ Bioorg Med Chem Lett (IF£º3)¡¢Tetrahedron Lett (IF£º3)£¬¶øÇÒÔøÓ¦ÑûÔÚÔÚ¶à¸ö¹ú¼ÊѧÊõ»áÒé×öÖØÒª±¨¸æ

¹ù´´Ð²©Ê¿ÔÚ2012Äê3ÔÂÖ÷¶¯´ÇÈ¥´ýÓö·áºñµÄ»ÔÈð¹¤×÷ºó£¬È«Ö°¼ÓÈëËÕÖÝ¿ªÍØÒ©ÒµÓÐÏÞ¹«Ë¾¡£ËÕÖÝ¿ªÍØÒ©Òµ³Ðµ£Á˹ú¼ÒÊ®¶þÎåÖØ´óÒ©Îï´´ÖÆרÏîºÍ½­ËÕÊ¡¿Æ¼¼Ö§³Å¼Æ»®£¬¹ù²©Ê¿µÄÈ«Ö°¼ÓÃË´ó´ó¼ÓÇ¿ÐÂÒ©Ñз¢ÍŶÓ£¬ÎÞÂÛÊǶԹ«Ë¾µÄ·¢Õ¹»¹ÊÇÏîÄ¿µÄÍê³É´øÀ´¾Þ´ó¼ÛÖµ¡£ËûÄ¿Ç°µ£ÈοªÍØÒ©ÒµÊ×ϯ¿Æѧ¹Ù£¬³ÉΪ¿ªÍØÒ©Òµ×ܲÃͯÓÑÖ®²©Ê¿µÄÖ÷ÒªºÏ×÷»ï°é£¬²ÎÓ빫˾µÄÈÕ³£¹ÜÀí¼°·¢Õ¹·½ÏòµÄ¾ö²ß£¬²¢ÀûÓÃËû¶àÄêÔÚ¿ç¹úÒ©³§¹¤×÷Öн¨Á¢ÆðÀ´µÄÈËÂö·¢Õ¹¸ü¶àµÄ¿ÆÑкÏ×÷»ú»á¡¢ÕÐļ¸ß¶ËÈ˲źÍÎüÒý¹úÄÚÍâͶ×ʺÏ×÷»ú»á¡£ÓÉÓڻعúºóµÄ³öÉ«¹¤×÷£¬¹ù²©Ê¿ÔÚ2013Äê»ñµÃÁËÖÐ×鲿µÚ¾ÅÅú´´ÐÂÀࡰǧÈ˼ƻ®¡±ÌØƸר¼Ò³ÆºÅ¡£
2003Äê¡«ÖÁ½ñ£º»ÔÈð¶à¸ö½±Ï³ÐÈϱ¾È˶ÔPin1/PAK4/RAFÏîÄ¿Ëù×÷³öµÄ¹±Ï×

98Äê3Ô£ºÃÏɽ¶¼¹«Ë¾Ñо¿ÉúÂÃÐн±Ñ§½ð

96Äê1Ô¡«98Äê5Ô£º¹ú¼Ò¿Æѧ»ù½ð»á½±Ñ§½ð

96Äê1Ô¡«97Äê12Ô£º´÷ά¡¤ÂÞ˹½±Ñ§½ð£¬Æնɴóѧ°©Ö¢Ñо¿ÖÐÐÄ

94Äê4Ô£ºÊ¯»¯¹¤Òµ²¿°ä·¢µÄÆû³µ£¨ÆøÈܽº£©»¯ÓÍÆ÷ÇåÏ´ÒºÑз¢³É¾Í½±

93Äê4Ô£ºÓɹãÖÝ»¯¹¤Ñо¿Ôº°ä·¢µÄÆû³µ£¨ÆøÈܽº£©»¯ÓÍÆ÷ÇåÏ´ÒºÑз¢×¿Ô½Ñо¿½±

93Äê3Ô£ºÓÉÓɹãÖÝ»¯¹¤Ñо¿Ôº°ä·¢µÄÖƶ¨Ö²Îï±íÃæÇåÏ´¼ÁµÄÑз¢×¿Ô½Ñо¿½±


¿ÆÑй¤×÷ :
ÐÂÐÍ¿¹Ç°ÁÐÏÙ°©Ò»ÀàÐÂÒ©µÄÁÙ´²Ç°Ñо¿,¿ÎÌ⸱×鳤£¬¹ú¼Ò¿Æ¼¼ÖØ´óרÏî¡°ÖØ´óÐÂÒ©´´ÖÆ¡±2011ZX09102-001-05 £¨2011-2013£©£¬Ä¿Ç°ÒѾ­½áÌâ

ÐÂÐÍ¿¹Ç°ÁÐÏÙ°©Ò»ÀàÐÂÒ©µÄÁÙ´²Ç°Ñо¿,¿ÎÌ⸱×鳤£¬½­ËÕÊ¡¿Æ¼¼Ö§³Å¼Æ»®£¨Éç»á·¢Õ¹£©BE** £¨2011-2014£©£¬Ä¿Ç°ÒѾ­½áÌâ

ÐÂÐÍ¿¹Ç°ÁÐÏÙ°©Ò»ÀàÐÂÒ©µÄÁÙ´²Ç°Ñо¿,¿ÎÌ⸱×鳤£¬ËÕÖÝÊпƼ¼¼Æ»® ZXY** £¨2012-2014£©£¬Ä¿Ç°ÒѾ­½áÌâ

PI3K/mTOR°ÐÏò¿¹°©Ò»ÀàÐÂÒ©Ñз¢£¬¿ÎÌ⸱×鳤£¬¿Æ¼¼²¿ÖÐСÆóÒµ´´Ð»ù½ð 12C**(2012-2014)£¬Ä¿Ç°ÒѾ­½áÌâ

¿¹Ç°ÁÐÏÙ°©ºÍÈéÏÙ°©1.1ÀàÐÂÒ©Æտ˳°·µÄÁÙ´²Ñо¿£¬¿ÎÌ⸺ÔðÈË£¬¹ú¼Ò¿Æ¼¼ÖØ´óרÏî¡°ÖØ´óÐÂÒ©´´ÖÆ¡±£¬2017ZX**£¨2017¡«2020£©£¬Ö´Ðйý³ÌÖÐ
1£®IDOÒÖÖƼÁÖƱ¸ºÍÖÊÁ¿Ñо¿ 2£®HedgehogÒÖÖƼÁÖƱ¸ºÍÖÊÁ¿Ñо¿

3£®ParpÒÖÖƼÁÖƱ¸ºÍÖÊÁ¿Ñо¿
Guo, C.* Linton, A. Jalaie, M. Kephart, S. Ornelas,M. Pairish, M. Greasley, S. Richardson, P. Maegley, K. Hickey, M. Li, J. Wu, X. Ji, C. Xie, Z. ¡°Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as Novel PKM2 Activators¡± BMCL £¨2013£©23 (11), 3358-3363.
Palmer, C. Pairish,M. Kephart, S. Bouzida,D. Cui,J. Deal, J. Dong, L. Gu, D. Linton,A. McAlpine, I. Yamazaki, S. Smith, E. John-Baptiste, A. Bagrodia, S. Kania, R. Guo, C.* ¡°Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug¨Cdrug interaction¡± BMCL (2012) 22(24), 7605-7609.
Guo, C.* McAlpine, I. Zhang, J. Knighton, D. Kephart, S. Johnson, C. Li, H. Bouzida, D. Yang, A. Dong, L. Marakovits, J. Tikhe, J. Richardson, P. Guo, L. Kania, R. Edwards, M. Kraynov, E. Christensen, J. Piraino, J. Lee, J. Dagostino, E. Del-Carmen C. Deng, Y. Smeal, T. Murray, B. ¡°Discovery of Pyrroloaminopyrazoles as Novel PAK Inhibitors¡± J. Med. Chem. (2012), 55(10), 4728-4739. Cited by F1000 ºÍNature SciBX as Top 2% paper¡£
Guo, C.* Pairish, M. Linton, A. Kephart, S. Ornelas, M. Nagata, A. Burke, B. Dong, L. Engbretsen, J. Fanjul, A.N. ¡° Design of Oxobenimidazoles and Oxindoles as Novel Androgen Receptor Antagonists¡± BMCL (2012) 22(7), 2572-2578.
Guo, C.* Kephart, S. Ornelas, M. Gonzales, J. Linton, A. Pairish, M. Nagata, A. Greasley, S. Elleraas, J. Hosea, N. Engebretsen, J. Fanjul, A.N. ¡°Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer¡± BMCL (2012) 22(2), 1230-1236.
Linton, A. Kang, P. Ornelas, M. Kephart, S. Hu, Q. Pairish, M., Jiang, Y. Guo, C.* ¡°Systematic structure modifications of imidazo[1,2-a]pyrimidine to reduce metabolism mediated by aldehyde oxidase (AO)¡± J. Med. Chem. (2011), 54(21), 7705-7712.
Guo, C.* Linton, A. Kephart, S. Ornelas, M. Pairish, M. Gonzalez, J. Greasley, S. Nagata, A. Burke, B.J. Edwards, M. Hosea, N. Kang, P. Hu, W. Engebretsen, J. Briere, D. Shi, M. Gukasyan, H. Richardson, P. Dack, K. Underwood, T. Johnson, P. Morell, A. Felstead, R. Kuruma, H. Matsimoto, H. Zoubeidi, A. Gleave, M. Los, G., Fanjul, A.N. ¡°Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists¡± J. Med. Chem. (2011), 54(21), 7693-7704.
Ornelas, M.* Gonzalez, J. Sach, N.W. Richardson, P. F. Bunker, K.D. Linton, A. Kephart, S. Pairish, S.E., Pairish, M. Guo, C. ¡°An efficient synthesis of highly functionalized chiral lactams¡± Tetrahedron Letters (2011), 52(37), 4760-4763.
Guo, C.* Dong, L. Marakovits, J. Kephart, S. ¡°A novel method to enable SNAr reaction of aminopyrrolopyrazoles¡± Tetrahedron Letters (2011), 52(14), 1692-1696.
Murray B.W* Guo C. Piraino J. Westwick J. K Zhang C. Lamerdin J. Dagostino E. Knighton D. Loi C.-M. Zager M. Kraynov E. Popoff I. Christensen J. G Martinez R. Kephart S. Marakovits J. Karlicek S. Bergqvist S. Smeal T. ¡°Small-molecule p21-activated kinase inhibitor PF-** is a potent inhibitor of oncogenic signaling and tumor growth.¡± Proceedings of the National Academy of Sciences of the United States of America (2010), 107(20), 9446-51. Cited by F1000 as Top 2% paper¡£
Guo, C.* Dong, L. Kephart, S. Hou, X. ¡°An efficient synthesis of sulfamides.¡± Tetrahedron Letters (2010), 51(21), 2909-2913.
Dong, L. Marakovits, J. Hou, X. Guo, C.* Greasley, S. Dagostino, E. Ferre, R.A. Johnson, M. C. Kraynov, E. Thomson, J. Pathak, V. Murray, B. W. ¡°Structure-based design of novel human Pin1 inhibitors (II).¡± Bioorganic & Medicinal Chemistry Letters (2010), 20(7), 2210-2214.
ÖúÀí¹¤³Ìʦ 1990¡«1992 Öйú ¹ãÖÝ»¯¹¤Ñо¿Ôº

Ñо¿Ô± 1998¡«2000 ÃÀ¹ú Agouron¹«Ë¾

¸ß¼¶Ñо¿Ô± 2000¡«2003 ÃÀ¹ú »ÔÈð

¸ß¼¶Ê×ϯ¿Æѧ¼Ò 2003¡«2008 ÃÀ¹ú »ÔÈð

¿ÆÑÐÊÒÖ÷ÈÎ 2007¡«2011 ÃÀ¹ú »ÔÈð

ѧÊõίԱ 2011¡«2012 ÃÀ¹ú »ÔÈð

Ê×ϯ¿Æѧ¹Ù 2012¡«ÖÁ½ñ ËÕÖÝ¿ªÍØÒ©Òµ¹É·ÝÓÐÏÞ¹«Ë¾


½ÌÓý±³¾° :
ѧʿ1986/09¡«1990/07 ±±¾©´óѧ »¯Ñ§

˶ʿ 1992/09 ¡« 1994/08 ÃÀ¹ú£¨USA£© ŦԼÖÝÁ¢´óѧ Óлú»¯Ñ§

²©Ê¿ 1994/09 ¡« 1998/05 ÃÀ¹ú£¨USA£© Æնɴóѧ Óлú»¯Ñ§
˶ʿ£¨Master£© 1992/09 ¡« 1994/08 ÃÀ¹ú£¨USA£© ŦԼÖÝÁ¢´óѧ Óлú»¯Ñ§

²©Ê¿£¨Ph.D£© 1994/09 ¡« 1998/05 ÃÀ¹ú£¨USA£© Æնɴóѧ Óлú»¯Ñ§